These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 10390074)

  • 41. Immunological and clinical effects of post-transplant G-CSF versus placebo in T-cell replete allogeneic blood transplant patients: results from a randomized double-blind study.
    Joshi SS; Bishop MR; Lynch JC; Tarantolo SR; Abhyankar S; Bierman PJ; Vose JM; Geller RB; McGuirk J; Foran J; Bociek RG; Hadi A; Day SD; Armitage JO; Kessinger A; Pavletic ZS
    Cytotherapy; 2003; 5(6):542-52. PubMed ID: 14660050
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Single-cell cloning of human, donor-derived antileukemia T-cell lines for in vitro separation of graft-versus-leukemia effect from graft-versus-host reaction.
    Montagna D; Daudt L; Locatelli F; Montini E; Turin I; Lisini D; Giorgiani G; Bernardo ME; Maccario R
    Cancer Res; 2006 Jul; 66(14):7310-6. PubMed ID: 16849581
    [TBL] [Abstract][Full Text] [Related]  

  • 43. IL-2 activated NK cell immunotherapy of three children after haploidentical stem cell transplantation.
    Koehl U; Sörensen J; Esser R; Zimmermann S; Grüttner HP; Tonn T; Seidl C; Seifried E; Klingebiel T; Schwabe D
    Blood Cells Mol Dis; 2004; 33(3):261-6. PubMed ID: 15528141
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Combinational IL-2/IL-15 induction does not further enhance IL-15-induced lymphokine-activated killer cell cytotoxicity against human leukemia/lymphoma cells.
    Ozdemir O; Savaşan S
    Clin Immunol; 2005 Jun; 115(3):240-9. PubMed ID: 15893691
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Increased non-major histocompatibility complex-restricted lytic activity in melanoma patients vaccinated with cytokine gene-transfected autologous tumor cells.
    Möller P; Möller H; Sun Y; Dorbic T; Henz BM; Wittig B; Schadendorf D
    Cancer Gene Ther; 2000 Jul; 7(7):976-84. PubMed ID: 10917199
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Kinetic of regulatory CD25high and activated CD134+ (OX40) T lymphocytes during acute and chronic graft-versus-host disease after allogeneic bone marrow transplantation.
    Sanchez J; Casaño J; Alvarez MA; Roman-Gomez J; Martin C; Martinez F; Gomez P; Serrano J; Herrera C; Torres A
    Br J Haematol; 2004 Sep; 126(5):697-703. PubMed ID: 15327522
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Autologous peripheral blood stem cell transplantation with induction of autologous graft-versus-host disease in acute myeloid leukemia.
    Park J; Lee MH; Lee HR; Park SH; Lee SH; Lee KE; Lee H; Park JO; Kim K; Jung CW; Im YH; Kang WK; Ko YH; Park K
    Bone Marrow Transplant; 2003 Nov; 32(9):889-95. PubMed ID: 14561989
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Cytolytic effector mechanisms and gene expression in autologous graft-versus-host disease: distinct roles of perforin and Fas ligand.
    Miura Y; Thoburn CJ; Bright EC; Hess AD
    Biol Blood Marrow Transplant; 2004 Mar; 10(3):156-70. PubMed ID: 14993881
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Biological, histological, and clinical impact of preoperative IL-2 administration in radically operable gastric cancer patients.
    Romano F; Cesana G; Berselli M; Gaia Piacentini M; Caprotti R; Bovo G; Uggeri F
    J Surg Oncol; 2004 Dec; 88(4):240-7. PubMed ID: 15565596
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Amplification of the graft-versus-leukemia effect in man by interleukin-2.
    Verdonck LF; van Heugten HG; Giltay J; Franks CR
    Transplantation; 1991 May; 51(5):1120-4. PubMed ID: 2031266
    [No Abstract]   [Full Text] [Related]  

  • 51. Interleukin-2 +/- lymphocytes as consolidative immunotherapy after autologous bone marrow transplantation for hematologic malignancies.
    Fefer A; Benyunes M; Higuchi C; York A; Massumoto C; Lindgren C; Buckner CD; Thompson JA
    Acta Haematol; 1993; 89 Suppl 1():2-7. PubMed ID: 8475668
    [TBL] [Abstract][Full Text] [Related]  

  • 52. IL-2/LAK therapy for refractory acute monoblastic leukemia relapsing after unrelated allogeneic bone marrow transplantation.
    Nagayama H; Takahashi S; Takahashi T; Ogami K; Ikebuchi K; Tojo A; Tani K; Asano S
    Bone Marrow Transplant; 1999 Jan; 23(2):183-5. PubMed ID: 10197806
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Interleukin-2 in autologous bone marrow transplantation.
    Charak BS
    Natl Med J India; 1993; 6(1):19-22. PubMed ID: 8453356
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Harnessing graft versus leukemia: implications for IL-2 treatment.
    Sondel PM; Kawai H; Wesly OH
    Bone Marrow Transplant; 1992; 10 Suppl 1():13-5. PubMed ID: 1521084
    [No Abstract]   [Full Text] [Related]  

  • 55. Lymphokine-activated killer cytotoxicity against leukaemic blast cells.
    Tratkiewicz JA; Szer J; Boyd RL
    Clin Exp Immunol; 1990 Apr; 80(1):94-9. PubMed ID: 2323104
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Acute myeloid leukaemia cells secrete a soluble factor that inhibits T and NK cell proliferation but not cytolytic function--implications for the adoptive immunotherapy of leukaemia.
    Orleans-Lindsay JK; Barber LD; Prentice HG; Lowdell MW
    Clin Exp Immunol; 2001 Dec; 126(3):403-11. PubMed ID: 11737054
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Induction of cutaneous 'graft-versus-host like' reaction by recombinant IL-2 after autologous bone marrow transplantation.
    Costello R; Blaise D; Jacquemier J; Monges G; Stoppa AM; Viens P; Olive D; Bouabdallah M; Brandely ; Gastaut JA
    Bone Marrow Transplant; 1995 Jul; 16(1):199-200. PubMed ID: 7581125
    [No Abstract]   [Full Text] [Related]  

  • 58. Cytokines in GvH and GvL.
    Holler E; Kolb HJ; Eissner G; Wilmanns W
    Bone Marrow Transplant; 1998 Dec; 22 Suppl 4():S3-6. PubMed ID: 9916621
    [No Abstract]   [Full Text] [Related]  

  • 59. Thrombocytopenia in acute leukaemia patients treated with IL2: cytolytic effect of LAK cells on megakaryocytic progenitors.
    Guarini A; Sanavio F; Novarino A; Gillio Tos A; Aglietta M; Foa R
    Br J Haematol; 1991 Nov; 79(3):451-6. PubMed ID: 1751372
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Dynamics of cytotoxicity of blood mononuclear cells in patients with bladder cancer during endolymphatic immunotherapy with lymphokine- activated killer cells and recombinant interleukin-2].
    Malakhova NV; Figurin KM; Fedorova NS; Kiselevskiĭ MV; Bykovskaia SN
    Biull Eksp Biol Med; 1996 Feb; 121(2):188-91. PubMed ID: 9026128
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.